Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MRSN NASDAQ:PLUR NASDAQ:QLGN NASDAQ:XFOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRSNMersana Therapeutics$8.28+3.5%$7.22$5.21▼$70.75$41.32M0.945,066 shs75,589 shsPLURPluri$4.62-1.8%$4.90$3.33▼$7.13$37.64M0.665,892 shs10,302 shsQLGNQualigen Therapeutics$5.23-6.4%$2.63$1.61▼$10.45$8.89M0.324.81 million shs265,031 shsXFORX4 Pharmaceuticals$3.48$3.00$1.35▼$26.83$39.71M0.54428,182 shs212,109 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRSNMersana Therapeutics0.00%+9.38%+21.41%+8.84%-84.38%PLURPluri0.00%+5.37%-9.49%-20.29%-11.08%QLGNQualigen Therapeutics0.00%+3.36%+209.47%+54.28%-36.80%XFORX4 Pharmaceuticals0.00%+0.58%-0.57%+106.53%-81.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRSNMersana Therapeutics$8.28+3.5%$7.22$5.21▼$70.75$41.32M0.945,066 shs75,589 shsPLURPluri$4.62-1.8%$4.90$3.33▼$7.13$37.64M0.665,892 shs10,302 shsQLGNQualigen Therapeutics$5.23-6.4%$2.63$1.61▼$10.45$8.89M0.324.81 million shs265,031 shsXFORX4 Pharmaceuticals$3.48$3.00$1.35▼$26.83$39.71M0.54428,182 shs212,109 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRSNMersana Therapeutics0.00%+9.38%+21.41%+8.84%-84.38%PLURPluri0.00%+5.37%-9.49%-20.29%-11.08%QLGNQualigen Therapeutics0.00%+3.36%+209.47%+54.28%-36.80%XFORX4 Pharmaceuticals0.00%+0.58%-0.57%+106.53%-81.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMRSNMersana Therapeutics 2.71Moderate Buy$56.60583.57% UpsidePLURPluri 2.00Hold$12.00160.02% UpsideQLGNQualigen Therapeutics 1.00SellN/AN/AXFORX4 Pharmaceuticals 2.50Moderate Buy$34.17881.80% UpsideCurrent Analyst Ratings BreakdownLatest QLGN, MRSN, PLUR, and XFOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025MRSNMersana TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025PLURPluriWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025QLGNQualigen TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025XFORX4 PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/29/2025XFORX4 PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $9.008/14/2025MRSNMersana TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$250.00 ➝ $36.008/14/2025MRSNMersana TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$125.00 ➝ $30.008/13/2025MRSNMersana TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.008/13/2025XFORX4 PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$7.00 ➝ $3.50(Data available from 10/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMRSNMersana Therapeutics$40.50M1.02N/AN/A($1.92) per share-4.31PLURPluri$1.34M28.17N/AN/A($0.11) per share-41.95QLGNQualigen Therapeutics$4.98M1.79N/AN/A($4.12) per share-1.27XFORX4 Pharmaceuticals$2.56M15.51N/AN/A$3.90 per share0.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMRSNMersana Therapeutics-$69.19M-$14.62N/AN/AN/A-212.94%N/A-54.85%11/12/2025 (Estimated)PLURPluri-$22.58M-$5.17N/A∞N/A-1,701.19%-4,191.91%-88.27%N/AQLGNQualigen Therapeutics-$6.26MN/A0.00∞N/AN/AN/A-202.16%11/13/2025 (Estimated)XFORX4 Pharmaceuticals-$37.45M-$14.84N/AN/AN/A-311.15%-375.31%-72.87%11/12/2025 (Estimated)Latest QLGN, MRSN, PLUR, and XFOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/17/2025Q4 2025PLURPluri-$0.73-$2.62-$1.89-$2.62$0.40 million$0.91 million8/14/2025Q2 2025QLGNQualigen TherapeuticsN/A-$1.00N/A-$1.00N/AN/A8/13/2025Q2 2025MRSNMersana Therapeutics-$3.75-$4.08-$0.33-$4.87$6.06 million$3.06 million8/8/2025Q2 2025XFORX4 Pharmaceuticals-$4.53-$3.47+$1.06-$3.47$1.62 million$1.97 million7/21/2025Q1 2025QLGNQualigen TherapeuticsN/A-$1.82N/A-$1.82N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMRSNMersana TherapeuticsN/AN/AN/AN/AN/APLURPluriN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/AXFORX4 PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMRSNMersana TherapeuticsN/A1.351.35PLURPluri51.650.680.68QLGNQualigen TherapeuticsN/A0.710.71XFORX4 Pharmaceuticals19.103.193.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMRSNMersana Therapeutics93.92%PLURPluri16.59%QLGNQualigen Therapeutics3.18%XFORX4 Pharmaceuticals72.03%Insider OwnershipCompanyInsider OwnershipMRSNMersana Therapeutics13.00%PLURPluri25.93%QLGNQualigen Therapeutics1.80%XFORX4 Pharmaceuticals2.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMRSNMersana Therapeutics1504.99 million4.34 millionOptionablePLURPluri1508.16 million6.04 millionOptionableQLGNQualigen Therapeutics501.70 million1.66 millionNot OptionableXFORX4 Pharmaceuticals8011.41 million11.16 millionOptionableQLGN, MRSN, PLUR, and XFOR HeadlinesRecent News About These CompaniesX4 Pharmaceuticals announces restructuring, 50% reduction in workforceSeptember 17, 2025 | msn.comX4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value CreationSeptember 17, 2025 | globenewswire.comX4 Pharmaceuticals files to sell 59.89M shares of common stock for holdersSeptember 11, 2025 | msn.comX4 Pharmaceuticals Announces Board Resignations and AppointmentsAugust 25, 2025 | msn.comX4 Pharmaceuticals Grants Inducement Equity Awards to New Executive OfficersAugust 15, 2025 | quiverquant.comQX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 15, 2025 | globenewswire.comX4 Pharmaceuticals Closes $85M Private Placement DealAugust 14, 2025 | theglobeandmail.comX4 Pharmaceuticals price target lowered to $3.50 from $7 at H.C. WainwrightAugust 13, 2025 | msn.comX4 Pharmaceuticals Stock Rises On Closing Of Upsized Offering, But Brokerage Lowers Price TargetAugust 13, 2025 | msn.comX4 Pharmaceuticals Announces Closing of Upsized $85 Million Private PlacementAugust 13, 2025 | globenewswire.comX4 Pharmaceuticals announces $60M financing, management changesAugust 12, 2025 | msn.comX4 Pharmaceuticals Announces $60M Equity FinancingAugust 12, 2025 | msn.comX4 Pharmaceuticals secures $60M PIPE financingAugust 12, 2025 | msn.comX4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board LeadershipAugust 12, 2025 | globenewswire.comX4 Pharmaceuticals, Inc. (XFOR) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comX4 Pharmaceuticals Inc News (XFOR) - Investing.comJuly 2, 2025 | investing.comXFOR X4 Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comX4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)June 16, 2025 | globenewswire.comX4 Pharmaceuticals Gets Fast Track Regulatory Designation for Neutropenia DrugJune 10, 2025 | marketwatch.comX4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropeniaJune 10, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQLGN, MRSN, PLUR, and XFOR Company DescriptionsMersana Therapeutics NASDAQ:MRSN$8.28 +0.28 (+3.50%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$8.05 -0.23 (-2.78%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Pluri NASDAQ:PLUR$4.62 -0.09 (-1.81%) Closing price 10/3/2025 03:56 PM EasternExtended Trading$4.62 0.00 (0.00%) As of 10/3/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.Qualigen Therapeutics NASDAQ:QLGN$5.23 -0.36 (-6.44%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$5.32 +0.09 (+1.82%) As of 04:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.X4 Pharmaceuticals NASDAQ:XFOR$3.48 0.00 (0.00%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$3.44 -0.04 (-1.01%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
